Safety and Early Signs of Efficacy of IL12-L19L19. (DODEKA)

• ClinicalTrials.gov Identifier: NCT04471987
• Recruitment Status: Recruiting
• First Posted: July 15, 2020
• Last Update Posted: April 8, 2024
• Sponsor: Philogen S.p.A.
• Information provided by (Responsible Party): Philogen S.p.A.

Tracking Information

• First Submitted Date: July 7, 2020
• First Posted Date: July 15, 2020
• Last Update Posted Date: April 8, 2024
• Actual Study Start Date: July 1, 2020
• Estimated Primary Completion Date: December 2025 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: July 13, 2020)

• For Part I: DLT [ Time Frame: From Day 1 to Day 28 of the treatment ]
  Occurrence of dose limiting toxicity (DLT) in dose escalation part of the study.
• For Part I: MAD [ Time Frame: From the enrollment of each patient until the completion of the treatment (for a maximum of 8 weeks) ]
  Definition of Maximum Administered Dose (MAD) (in dose escalation part). The MAD is defined when at least two patients within a cohort of 2-6 patients experience a DLT (i.e., ≥33% of patients with a DLT at that dose level)
• For Part I: MTD [ Time Frame: From the enrollment of each patient until the completion of the treatment (for a maximum of 8 weeks) ]
  Defining the Maximum Tolerated Dose (MTD) and recommendation of the Recommended Dose (RD): when the DLT rate reaches 33% in a cohort, the next lower dose level will be called the MTD (so long as the DLT rate is less than 33%). Accordingly, the recommended dose (RD) for the Dose Expansion cohort will be the MTD.
• Safety (AE) [ Time Frame: Throughout study completion for each patient, a maximum of 24 weeks for each patient ]
  Safety of administration of IL12-L19L19, through an assessed by Common Toxicity Criteria (version 5.0, CTCAE)
• Safety (SAE) [ Time Frame: Throughout study completion for each patient, a maximum of 24 weeks for each patient ]
  Safety of administration of IL12-L19L19, assessed by Common Toxicity Criteria (version 5.0, CTCAE)
• Safety (DILI) [ Time Frame: Throughout study completion for each patient, a maximum of 24 weeks for each patient ]
  Evaluation of possible Drug Induce Liver Injury, caused by IL12-L19L19, assessed by Common Toxicity Criteria (version 5.0, CTCAE)

• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: December 6, 2022)

• Plasma concentration of IL12-L19L19 [ Time Frame: 30 min prior injection in week from 1 to 8, at End-of-Treatment Visit and Follow Up 1; in week 1 and 3: 15 min after start of infusion, 60 min after start of infusion, end of infusion, 2h, 4h and 24h after end of infusion ]
  Evaluation of individual plasma concentration of IL12-L19L19
• AUC of IL12-L19L19 [ Time Frame: In week 1 and 3: 15 min after start of infusion, 60 min after start of infusion, end of infusion, 2 h after end of infusion, 4 h after end of infusion, 24 h after end of infusion ]
  Estimation of AUC of IL12-L19L19, as data permit
• Tmax of IL12-L19L19 [ Time Frame: In week 1 and 3: 15 min after start of infusion, 60 min after start of infusion, end of infusion, 2 h after end of infusion, 4 h after end of infusion, 24 h after end of infusion ]
  Estimation of Tmax of IL12-L19L19, as data permit
• T1/2 of IL12-L19L19 [ Time Frame: in week 1 and 3: 15 min after start of infusion, 60 min after start of infusion, end of infusion, 2 h after end of infusion, 4 h after end of infusion, 24 h after end of infusion ]
  Estimation of T1/2 of IL12-L19L19, as data permit
• Cmax of IL12-L19L19 [ Time Frame: in week 1 and 3: 15 min after start of infusion, 60 min after start of infusion, end of infusion, 2 h after end of infusion, 4 h after end of infusion, 24 h after end of infusion ]
  Estimation of Cmax of IL12-L19L19, as data permit
• HAFA [ Time Frame: At week 1, 2, 3 and 4 ]
  Formation of human anti-fusion protein antibodies (HAFA) against IL12-L19L19
• For Part II: ORR [ Time Frame: At 8 weeks, 16 weeks, 24 weeks, 36 weeks and 48 weeks. ]
  Objective Response Rate (ORR, consisting of complete response (CR) + partial response (PR)), is defined as the proportion of patients with tumor size reduction of a predefined amount and for a minimum time period. Response duration usually is measured from the time of initial response until documented tumor progression. ORR is the sum of partial responses (PR) plus complete responses (CR), based on Response Evaluation Criteria in Solid Tumors (RECIST) (v. 1.1) criteria.
• PFS [ Time Frame: At 24 weeks and 48 weeks. ]
  Progression Free Survival (PFS) the time from enrolment to progression or death from any cause.
• OS [ Time Frame: At 24 weeks and 48 weeks. ]
  Overall Survival (OS) is defined beginning from enrolment to death from any cause

Original Secondary Outcome Measures (submitted: July 13, 2020)

• Plasma concentration of IL12-L19L19 [ Time Frame: 30 min prior injection in week from 1 to 8, at End-of-Treatment Visit and Follow Up 1; in week 1 and 3: 15 min after start of infusion, 60 min after start of infusion, end of infusion, 2h, 4h and 24h after end of infusion ]
  Evaluation of individual plasma concentration of IL12-L19L19
• AUC of IL12-L19L19 [ Time Frame: In week 1 and 3: 15 min after start of infusion, 60 min after start of infusion, end of infusion, 2 h after end of infusion, 4 h after end of infusion, 24 h after end of infusion ]
  Estimation of AUC of IL12-L19L19, as data permit
• Tmax of IL12-L19L19 [ Time Frame: In week 1 and 3: 15 min after start of infusion, 60 min after start of infusion, end of infusion, 2 h after end of infusion, 4 h after end of infusion, 24 h after end of infusion ]
  Estimation of Tmax of IL12-L19L19, as data permit
• T1/2 of IL12-L19L19 [ Time Frame: in week 1 and 3: 15 min after start of infusion, 60 min after start of infusion, end of infusion, 2 h after end of infusion, 4 h after end of infusion, 24 h after end of infusion ]
  Estimation of T1/2 of IL12-L19L19, as data permit
• Cmax of IL12-L19L19 [ Time Frame: in week 1 and 3: 15 min after start of infusion, 60 min after start of infusion, end of infusion, 2 h after end of infusion, 4 h after end of infusion, 24 h after end of infusion ]
  Estimation of Cmax of IL12-L19L19, as data permit
• HAFA [ Time Frame: At week 1, 2, 3 and 4 ]
  Formation of human anti-fusion protein antibodies (HAFA) against IL12-L19L19
• For Part II: ORR [ Time Frame: At 8 weeks, 16 weeks and 24 weeks. ]
  Objective Response Rate (ORR, consisting of complete response (CR) + partial response (PR)), is defined as the proportion of patients with tumor size reduction of a predefined amount and for a minimum time period. Response duration usually is measured from the time of initial response until documented tumor progression. ORR is the sum of partial responses (PR) plus complete responses (CR), based on Response Evaluation Criteria in Solid Tumors (RECIST) (v. 1.1) criteria for solid tumors or by LUGANO criteria for DLBCL.
• For Part II: DCR [ Time Frame: At 8 weeks, 16 weeks and 24 weeks. ]
  Disease Control Rate (DCR, consisting of CR, PR +SD) is the percentage of patients whose disease shrinks or remains stable over a certain time period. DCR is the sum of the complete, partial and stable disease rates based on Response Evaluation Criteria in Solid Tumors (RECIST) (v. 1.1) criteria for solid tumors or by LUGANO criteria for DLBCL.

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Safety and Early Signs of Efficacy of IL12-L19L19.
• Official Title: A Phase I Study to Evaluate Safety and Early Signs of Efficacy of the Human Monoclonal Antibody-cytokine Fusion Protein IL12-L19L19.

Brief Summary

The purpose of this study is to describe the safety, tolerability and early signs of efficacy of the antibody-cytokine fusion protein IL12-L19L19 in patients with advanced or metastatic solid carcinomas, after previous immune checkpoint blockade therapy.

The primary objective of the study is to evaluate the safety of IL12-L19L19 and to establish MTD in order to establish a recommended dose (RD).

The secondary objectives of the study are to assess early signs of efficacy, the determination of pharmacokinetic (PK) properties and the immunogenicity of IL12-L19L19.

• Detailed Description: Not Provided
• Study Type: Interventional
• Study Phase: Phase 1

Study Design

Allocation: N/A
Intervention Model: Sequential Assignment
Intervention Model Description:

Prospective, open-label, non-randomized, multiple ascending dose, phase I dose escalation trial in patients with advanced solid carcinomas after previous immune-checkpoint blockade therapy conducted in sequential cohorts of patients followed by a dose expansion part.

Masking: None (Open Label)
Primary Purpose: Treatment

Condition

• Advanced Solid Tumor
• Metastatic Solid Tumor

Intervention

• Drug: IL12-L19L19

  Part I - The dose escalation is designed with an initial accelerated phase followed by a standard 3+3 design. Cohorts contain one patient until first instance of moderate toxicity or a DLT in the DLT observation period (28 days). With the second occurrence of moderate toxicity or occurrence of a DLT the accelerated phase will be terminated and the dose escalation will continue with a 3+3 dose escalation. Initiation of the study treatment for an individual subject will occur not less than 7 days after initiation of the study treatment for the previous patient. Not more than 2 patients are to be treated simultaneously within their DLT observation period (i.e., Day 1 to Day 28).

  Part II - Dose expansion: Once the dose escalation is completed, additional 40 patients will be enrolled at the RD to better understand the safety profile and to explore early signs of efficacy in different disease indications.

  Other Name: Dodekin
• Drug: IL12-L19L19
  Patients initially receive 8 consecutive administrations of IL12-L19L19 every week. At the end of this eight weeks treatment window, a tumor assessment is performed and those patients who achieve a clinical benefit (SD, PR, CR) may continue treatment with IL12-L19L19 as a biweekly maintenance therapy until disease progression, unacceptable toxicity, withdrawal of consent, at the discretion of the investigator or up to 1 year from study treatment start.
  Other Name: Dodekin

Study Arms

Experimental: Treatment

The study will take place in two stages:

1. In the dose escalation part, participants will be enrolled in cohorts and will be treated with different doses of IL12-L19L19 in order to identify a RD to be further explored in the subsequent dose expansion part. In the dose escalation part, patients will be treated in cohorts of 1 to 6 patients with escalating doses of IL12-L19L19 until the MAD is reached.
2. Following successful identification of the RD, the study will proceed with a dose expansion part and 40 patients will be treated at the RD dose level.

Interventions:

• Drug: IL12-L19L19
• Drug: IL12-L19L19

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Recruiting
• Estimated Enrollment (submitted: July 13, 2020): 94
• Original Estimated Enrollment: Same as current
• Estimated Study Completion Date: December 2025
• Estimated Primary Completion Date: December 2025 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

1. Male or Female aged 18 to 80 years at the time of consent.
2. Patients must have a histological or cytological diagnosis of advanced/metastatic immunotherapy responsive solid carcinoma for which immune checkpoint blockade is approved, that has progressed on immune checkpoint-blockade therapy.
3. Patients must have received an immune checkpoint blockade therapy-based regimen as prior treatment.
4. Only patients without other therapeutic alternatives with curative or survival prolonging potential per investigator judgement are able to participate.
5. Subjects must have had clinical benefit in terms of disease control (CR/PR/SD) while on checkpoint inhibitor treatment defined as ≥ 3 month free from progression from initial imaging documenting advanced/metastatic disease followed by radiographic disease progression after checkpoint inhibitor per investigator's opinion.
6. Patients must have progressive disease or relapse at the time of screening.
7. Patients may have previously received chemotherapy, immunotherapy or radiation therapy. Such therapies must be completed at least 4 weeks prior to study drug administration. Radiotherapy within 4 weeks of the first dose of study drug, is allowed for palliative radiotherapy to a limited field, such as for the treatment of bone pain or a focally painful tumor mass. During the expansion part, to allow evaluation of response to treatment, patients must have remaining measurable disease that has not been irradiated.
8. Eastern cooperative oncology group (ECOG) performance status ≤ 2.
9. Patient has an estimated life expectancy of at least 12 weeks.
10. At least one unidimensionally measurable lesion either by computed tomography (CT), MRI or PET/CT as defined by RECIST (v. 1.1) for solid tumors.
11. Documented negative test for HIV-HBV-HCV. For HBV serology: the determination of HBsAg, and anti-HBcAg-Ab is required. In patients with serology documenting previous exposure to HBV (i.e., anti-HBs Ab with no history of vaccination and/or anti-HBc Ab), negative serum HBV-DNA is required. For HCV: HCV-RNA or HCV antibody test. Subjects with a positive test for HCV antibody but no detection of HCV-RNA indicating no current infection are eligible.
12. All acute toxic effects (excluding alopecia and fatigue) of any prior therapy (including surgery, radiation therapy, chemotherapy) must have resolved to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) (v. 5.0) Grade ≤ 1.
13. Full resolution of checkpoint blockade therapy-related adverse effects (including immune-related adverse effects) and no treatment for these AEs for at least 4 weeks prior to the time of enrollment. The only exception are patients with checkpoint blockade induced hypothyroidism and hypophysitis if these patients are on stable maintenance therapy with on levothyroxine or steroids (≤ 10 mg prednisone equivalent) for at least 2 months prior dosing.
14. No history of severe immune related adverse effects from prior given immune checkpoint blockade therapy (CTCAE Grade 4; CTCAE Grade 3 requiring treatment >4 weeks).
15. Female patients: negative blood pregnancy test at Screening for women of childbearing potential (WOCBP)*. WOCBP must agree to use, from the screening to six months following the last study drug administration, highly effective contraception methods, as defined by the "Recommendations for contraception and pregnancy testing in clinical trials" issued by the Head of Medicine Agencies' Clinical Trial Facilitation Group (www.hma.eu/ctfg.html) and which include, for instance, progesterone-only or combined (estrogen- and progesterone-containing) hormonal contraception associated with inhibition of ovulation, intrauterine devices, intrauterine hormone-releasing systems, bilateral tubal occlusion or vasectomized partner.
16. Male patients: male subjects able to father children must agree to use two acceptable methods of contraception throughout the study (e.g. condom with spermicidal gel). Double-barrier contraception is required.
17. Negative TB test (e.g. Mantoux or Quantiferon assay).
18. A personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study and has given consent to participate in the study.

19. Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures.

    • Women of childbearing potential are defined as females who have experienced menarche, are not postmenopausal (12 months with no menses without an alternative medical cause) and are not permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral oophorectomy or bilateral salpingectomy)

Informed consent must be obtained for all the patients prior to any screening procedure for the present study.

Exclusion Criteria:

1. Subjects who participated in an investigational drug or device study within 4 weeks prior to study treatment start.
2. Radiotherapy within 4 weeks prior to study treatment start.
3. Active or history of autoimmune disease that might deteriorate when receiving an immuno-stimulatory agent.
4. Patients with primary brain tumors or CNS disease.
5. Patient taking herbal medications within 7 days prior to study treatment start.
6. Known history of allergy to an excipient in study medication or any other intravenously administered human proteins/peptides/antibodies.
7. Absolute neutrophil count (ANC) < 1.5 x 10^9/L, platelets < 100 x 10^9/L or haemoglobin (Hb) < 9.0 g/dl.
8. Chronically impaired renal function as indicated by creatinine clearance < 60 mL/min or serum creatinine > 1.5 ULN.
9. Inadequate liver function (ALT, AST, ALP ≥ 2.5 x ULN or total bilirubin ≥ 2.0 x ULN). At the discretion of the investigator, an increased exclusion threshold for patients with liver metastasis can be accepted as follows: ALT, AST, ALP and bilirubin ≥ 5 x ULN.
10. Any severe concomitant condition which makes it undesirable for the patient to participate in the study or which could jeopardize compliance with the protocol, in the opinion of the investigator.
11. History within the last year of cerebrovascular disease and/or acute or subacute coronary syndromes including myocardial infarction, unstable or severe stable angina pectoris.
12. Heart insufficiency (> Grade II, New York Heart Association (NYHA) criteria).
13. Clinically significant cardiac arrhythmias or requiring permanent medication.

14. Abnormal LVEF or any other abnormalities observed during baseline ECG and echocardiogram investigations that are considered as clinically significant by the investigator. Subjects with current, or a history of QT/QTc prolongation would be excluded. In particular:

    • patients with a marked prolongation of QT/QTc interval (e.g., repeated demonstration of QTc >480 milliseconds using Fredricia's QT correction formula) are excluded;
    • patients with a history of risk factors for Torsades de Pointes (e.g., heart failure, hypokalemia, family history of prolonged QT syndrome) are excluded;
    • patients who require the use of concomitant medications that prolong the QT/QTc interval are excluded.
15. Uncontrolled hypertension as defined by systolic blood pressure ≥ 140 mmHg and diastolic blood pressure ≥ 90 mmHg at 3 consecutive measurements performed within one week. Note: if the first blood pressure measurement is below threshold for systolic or diastolic blood pressure, it is not required to repeat the measurement.
16. Ischemic peripheral vascular disease (Grade IIb-IV according to Leriche-Fontaine classification).
17. Severe diabetic retinopathy such as severe non-proliferative retinopathy and proliferative retinopathy.
18. Major trauma including major surgery (such as abdominal/cardiac/thoracic surgery) within 4 weeks of study treatment start.
19. Pregnancy or breast-feeding.
20. Systemic chronic steroid therapy (>10 mg/day prednisone or equivalent) or any other immunosuppressive therapy within 14 days prior to study treatment start. Topical, inhaled, nasal and ophthalmic steroids are allowed.
21. Presence of active and uncontrolled infections or other severe concurrent disease, which, in the opinion of the investigator, would place the patient at undue risk or interfere with the study.
22. Concurrent or previous malignancies (other than the indication for this trial), unless a complete remission without further recurrence was achieved at least 2 years prior to study treatment start.
23. Growth factors or immunomodulatory agents within 7 days prior to study treatment start.
24. Serious, non-healing wound, ulcer or bone fracture.
25. Deep vein thrombosis, pulmonary embolism or other acute vascular events within 6 months.
26. Requirement of concurrent use of other anti-cancer treatments or agents other than study medication.
27. Any recent live vaccination within 4 weeks prior to treatment or plan to receive vaccination during the study.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years to 80 Years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Contacts

Contact: Jacqueline Mock, PhD; +41 798708167; regulatory@philogen.com

Contact: Marco Taras, Biologist; +39 057717816; regulatory@philogen.com

• Listed Location Countries: Germany, Italy, Switzerland

Administrative Information

• NCT Number: NCT04471987
• Other Study ID Numbers: PH- IL12L19L19-01/19
• Has Data Monitoring Committee: Yes

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

IPD Sharing Statement

• Plan to Share IPD: No

• Current Responsible Party: Philogen S.p.A.
• Original Responsible Party: Same as current
• Current Study Sponsor: Philogen S.p.A.
• Original Study Sponsor: Same as current
• Collaborators: Not Provided
• Investigators: Not Provided
• PRS Account: Philogen S.p.A.
• Verification Date: April 2024